RESUMEN
Hepatorenal syndrome (HRS) is a feared complication in patients with advanced cirrhosis and is associated with significant morbidity and mortality. While recognized as a distinct physiologic condition for well over one hundred years, a lack of objective diagnostic tests has made the diagnosis one of exclusion. Since 1979, multiple sets of diagnostic criteria have been proposed. Though varying in detail, the principal intent of these criteria is to identify patients with severe, functional acute kidney injury that is unresponsive to volume resuscitation and exclude those with structural injury. However, accurate differential diagnosis remains challenging. Recently, multiple urinary biomarkers of kidney injury, including neutrophil gelatinase-associated lipocalin, have been studied as a means of objectively phenotyping etiologies of acute kidney injury in patients with cirrhosis. Along with markers reflecting tubular functional integrity, including the fractional excretion of sodium, injury markers will likely be incorporated into future diagnostic criteria. Making an accurate diagnosis is critical, as therapeutic options exist for HRS but must be given in a timely manner and only to those patients likely to benefit. Terlipressin, an analog of vasopressin, is the first line of therapy for HRS in much of the world and has recently been approved for use in the United States. Significant questions remain regarding the optimal dosing strategy, metrics for titration, and the potential role of point-of-care ultrasound to help guide concurrent albumin administration.
Asunto(s)
Biomarcadores , Síndrome Hepatorrenal , Terlipresina , Humanos , Síndrome Hepatorrenal/diagnóstico , Síndrome Hepatorrenal/terapia , Síndrome Hepatorrenal/etiología , Biomarcadores/orina , Terlipresina/uso terapéutico , Lipresina/análogos & derivados , Lipresina/uso terapéutico , Vasoconstrictores/uso terapéutico , Diagnóstico Diferencial , Lipocalina 2/orina , Lesión Renal Aguda/diagnóstico , Lesión Renal Aguda/terapiaAsunto(s)
Várices Esofágicas y Gástricas , Hemorragia Gastrointestinal , Cirrosis Hepática , Lipresina , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/administración & dosificación , Terlipresina/uso terapéutico , Cirrosis Hepática/complicaciones , Cirrosis Hepática/tratamiento farmacológico , Várices Esofágicas y Gástricas/tratamiento farmacológico , Hemorragia Gastrointestinal/tratamiento farmacológico , Hemorragia Gastrointestinal/etiología , Vasoconstrictores/administración & dosificación , Lipresina/análogos & derivados , Lipresina/administración & dosificación , Lipresina/uso terapéutico , Administración IntravenosaAsunto(s)
Cirrosis Hepática , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/uso terapéutico , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/complicaciones , Vasoconstrictores/efectos adversos , Vasoconstrictores/uso terapéutico , Lipresina/análogos & derivados , Lipresina/uso terapéutico , Lipresina/efectos adversosAsunto(s)
Várices Esofágicas y Gástricas , Hemorragia Gastrointestinal , Cirrosis Hepática , Lipresina , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/administración & dosificación , Terlipresina/uso terapéutico , Cirrosis Hepática/complicaciones , Cirrosis Hepática/tratamiento farmacológico , Várices Esofágicas y Gástricas/tratamiento farmacológico , Hemorragia Gastrointestinal/tratamiento farmacológico , Hemorragia Gastrointestinal/etiología , Vasoconstrictores/administración & dosificación , Lipresina/análogos & derivados , Lipresina/administración & dosificación , Lipresina/uso terapéutico , Administración IntravenosaRESUMEN
INTRODUCTION AND OBJECTIVES: Hepatorenal syndrome (HRS) is a serious complication of cirrhosis treated with various medications. We aim to evaluate terlipressin and albumin's effectiveness and safety compared to albumin and noradrenaline in adult hepatorenal disease patients. MATERIALS AND METHODS: Clinical trials from four databases were included. Cochrane's approach for calculating bias risk was utilized. We rated the quality evaluation by Grading of Recommendations Assessment, Development, and Evaluation (GRADE). We included the following outcomes: serum creatinine (mg/dl), urine output (ml/24 h), mean arterial pressure (mmHg), reversal rate of HRS, mortality rate, blood plasma renin activity (ng/ml/h), plasma aldosterone concentration (pg/ml), urine sodium (mEq/l), and creatinine clearance (ml/min). RESULTS: Our analysis of nine clinical studies revealed that the noradrenaline group was associated with higher creatinine clearance (MD = 4.22 [0.40, 8.05]), (P = 0.03). There were no significant differences in serum creatinine levels (MD = 0.03 [-0.07, 0.13]), urinary sodium (MD = -1.02 [-5.15, 3.11]), urine output (MD = 32.75 [-93.94, 159.44]), mean arterial pressure (MD = 1.40 [-1.17, 3.96]), plasma renin activity (MD = 1.35 [-0.17, 2.87]), plasma aldosterone concentration (MD = 55.35 [-24.59, 135.29]), reversal rate of HRS (RR = 1.15 [0.96, 1.37]), or mortality rate (RR = 0.87 [0.74, 1.01]) between the two groups (p-values > 0.05). CONCLUSIONS: Noradrenaline is a safe alternative medical therapy for HRS.
Asunto(s)
Albúminas , Síndrome Hepatorrenal , Norepinefrina , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/uso terapéutico , Síndrome Hepatorrenal/tratamiento farmacológico , Norepinefrina/uso terapéutico , Norepinefrina/orina , Norepinefrina/sangre , Albúminas/uso terapéutico , Resultado del Tratamiento , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversos , Adulto , Creatinina/sangre , Lipresina/análogos & derivados , Lipresina/uso terapéutico , Lipresina/efectos adversosAsunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Lipresina , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/uso terapéutico , Síndrome Hepatorrenal/tratamiento farmacológico , Lesión Renal Aguda/diagnóstico , Lipresina/análogos & derivados , Lipresina/uso terapéutico , Lipresina/efectos adversos , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversosAsunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Terlipresina , Vasoconstrictores , Humanos , Terlipresina/uso terapéutico , Síndrome Hepatorrenal/tratamiento farmacológico , Lesión Renal Aguda/diagnóstico , Lesión Renal Aguda/inducido químicamente , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversos , Lipresina/análogos & derivados , Lipresina/efectos adversos , Lipresina/uso terapéuticoAsunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Terlipresina , Vasoconstrictores , Terlipresina/uso terapéutico , Humanos , Síndrome Hepatorrenal/tratamiento farmacológico , Lesión Renal Aguda/tratamiento farmacológico , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversos , Lipresina/análogos & derivados , Lipresina/uso terapéuticoAsunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Terlipresina , Vasoconstrictores , Terlipresina/uso terapéutico , Humanos , Síndrome Hepatorrenal/tratamiento farmacológico , Lesión Renal Aguda/tratamiento farmacológico , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversos , Lipresina/análogos & derivados , Lipresina/uso terapéuticoAsunto(s)
Lesión Renal Aguda , Síndrome Hepatorrenal , Terlipresina , Vasoconstrictores , Terlipresina/uso terapéutico , Humanos , Síndrome Hepatorrenal/tratamiento farmacológico , Lesión Renal Aguda/tratamiento farmacológico , Vasoconstrictores/uso terapéutico , Vasoconstrictores/efectos adversos , Lipresina/análogos & derivados , Lipresina/uso terapéutico , Lipresina/efectos adversosAsunto(s)
Terlipresina , Humanos , Terlipresina/administración & dosificación , Gabapentina/administración & dosificación , Gabapentina/uso terapéutico , Vasoconstrictores/administración & dosificación , Vasoconstrictores/efectos adversos , Lipresina/análogos & derivados , Lipresina/administración & dosificación , Lipresina/efectos adversos , MasculinoRESUMEN
BACKGROUND: Continuous infusion of terlipressin causes more stable reduction in portal venous pressure than intermittent infusion. The aim of the study was to compare the efficacy of continuous infusion vs. intermittent boluses of terlipressin to control acute variceal bleeding (AVB) in patients with portal hypertension. METHODS: Eighty-six consecutive patients with portal hypertension and AVB were randomized to receive either continuous intravenous infusion (Group A, n = 43) or intravenous boluses of terlipressin (Group B, n = 43). Group A received 1 mg intravenous bolus of terlipressin followed by a continuous infusion of 4 mg in 24 h. Group B received 2 mg intravenous bolus of terlipressin followed by 1 mg intravenous injection every 6 h. Upper gastrointestinal (UGI) endoscopy was done within 12 h of admission. Endoscopic variceal ligation (EVL) was done using a multi-band ligator. In both groups, treatment was continued up to 5 days. The primary endpoint was rebleeding or death within 5 days of admission. RESULTS: Patients in group A had lower rate of treatment failure (4.7%) as compared to patients in group B (20.7%) (p = 0.02). Within 6 weeks, four and eight patients died in group A and B, respectively (p = 0.21). Model for end-stage liver disease sodium (MELD-Na) score and continuous infusion of terlipressin showed significant relationship with treatment failure on multivariate analysis. CONCLUSIONS: Continuous infusion of terlipressin may be more effective than intermittent infusion to prevent treatment failure in patients with variceal bleeding. There is significant relationship between MELD-Na score [Odd ratio = 1.37 (95% CI-1.16 - 1.62), p-value < 0.001] and continuous infusion of terlipressin [Odd ratio = 0.18 (95% CI-0.037 - 0.91), p-value - 0.04] with treatment failure.
Asunto(s)
Várices Esofágicas y Gástricas/tratamiento farmacológico , Várices Esofágicas y Gástricas/etiología , Hemorragia Gastrointestinal/tratamiento farmacológico , Hemorragia Gastrointestinal/etiología , Hipertensión Portal/complicaciones , Lipresina/análogos & derivados , Vasoconstrictores/administración & dosificación , Enfermedad Aguda , Adolescente , Adulto , Anciano , Esquema de Medicación , Femenino , Humanos , Infusiones Intravenosas , Inyecciones Intravenosas , Lipresina/administración & dosificación , Masculino , Persona de Mediana Edad , Presión Portal , Terlipresina , Resultado del Tratamiento , Adulto JovenRESUMEN
OBJECTIVE: To investigate the effects of terlipressin (TP) on blood pressure and survival in septic mice following trauma and its mechanism. METHODS: (1) Survival experiment: 120 male C57BL/6 mice aged 6-8 weeks were enrolled, the posttraumatic sepsis mice model was reproduced by traumatic hemorrhage (bilateral femoral fracture + 45% of total blood loss) followed by cecal ligation and puncture (CLP) after 8 hours. Intraperitoneal injection of TP was used for intervention. Sixty model mice were used to observe the effect of 0.05 µg/g TP at different intervention times (the drug was given immediately after traumatic hemorrhage + the administration was repeated after 6 hours, the drug was given immediately after traumatic hemorrhage + the administration was repeated every 6 hours until the end of the experiment, the drug was given at 4 hours after CLP + the administration was repeated every 6 hours until the end of the experiment) on 48-hour cumulative survival rate of mice with posttraumatic sepsis for finding the best intervention time of TP. The other 60 model mice were used to observe the effect of different TP intervention doses (0.01, 0.05, 0.25 µg/g) at the best intervention time on the 48-hour cumulative survival rate of mice with posttraumatic sepsis for finding the best intervention dose of TP. (2) Intervention experiment: the other 45 mice were enrolled, and they were randomly divided into traumatic hemorrhage + sham group (TH+sham group, only laparotomy without CLP), TH+CLP group, and TH+CLP+TP group (the best intervention time and dose of TP shown by survival experiment were used), with 15 mice in each group. Mean arterial pressure (MAP) of mice was monitored continuously. The orbital whole blood was collected at 2 hours after successful reproduction of the model, and the lung tissues were harvested at 12 hours and 24 hours, respectively. The pathological changes in lung tissue were observed with light microscope. The contents of interleukin-1ß (IL-1ß) and tumor necrosis factor-α (TNF-α) in serum and lung tissue were determined by enzyme linked immunosorbent assay (ELISA). The expressions of IL-1ß and TNF-α mRNA in lung tissue were determined by real-time quantitative reverse transcription-polymerase chain reaction (RT-qPCR). The expressions of nuclear factor-κB p65 (NF-κB p65) in the nucleus and cytoplasm of lung tissue were determined by Western Blot. RESULTS: (1) Survival experiment results showed that the 48-hour cumulative survival rate of mice was highest with TP intervention by 0.05 µg/g administration immediately after traumatic hemorrhage and repeated every 6 hours, which was the best intervention method of TP. (2) Intervention experiment results showed that the pulmonary alveolar wall fracture accompanied by inflammatory cell infiltration was found at 12 hours after the successful reproduction of traumatic sepsis model, and the pathological damage was gradually increased with time prolongation. MAP was decreased sharply after traumatic hemorrhage, and it was continued to decrease after two-hit of CLP. The contents of IL-1ß and TNF-α in serum and lung tissue, the expressions of IL-1ß and TNF-α mRNA in lung tissue, and expressions of NF-κB p65 protein in cytoplasm and nucleus of TH+CLP group were significantly higher than those in TH+sham group. Compared with TH+CLP group, the pathological changes in lung tissue were improved significantly, and the MAP was decreased gently after TP intervention, the levels of inflammatory mediators in serum were significantly decreased [IL-1ß (pg/L): 164.32±25.25 vs. 233.11±23.02, TNF-α (pg/L): 155.56±31.47 vs. 596.38±91.50, both P < 0.05], and their expressions in lung tissue [IL-1ß content (ng/mg): 262.68±16.56 vs. 408.15±17.85, IL-1ß mRNA (2-Δ ΔCt): 2.63±0.68 vs. 6.22±0.74; TNF-α content (ng/mg): 311.07±17.35 vs. 405.04±24.83, TNF-α mRNA (2-Δ ΔCt): 2.04±0.62 vs. 5.32±0.55, all P < 0.01], and NF-κB p65 protein expressions were significantly down-regulated (gray value: 0.47±0.01 vs. 1.28±0.05 in cytoplasm, 0.45±0.02 vs. 1.95±0.06 in nucleus, both P < 0.01]. CONCLUSIONS: The continuous intervention with TP 0.05 µg/g administration immediately after traumatic hemorrhage and repeated every 6 hours could improve the MAP of mice with traumatic sepsis, and improve the prognosis. The mechanism may be related to alleviating the inflammatory response and inhibiting the activation of the NF-κB signaling pathway in the lung tissue.
Asunto(s)
Presión Sanguínea , Animales , Interleucina-1beta , Lipresina/análogos & derivados , Masculino , Ratones , Ratones Endogámicos C57BL , Sepsis , Terlipresina , Factor de Necrosis Tumoral alfaRESUMEN
AIM: To evaluate the differences in acute kidney injury (AKI) between acute-on-chronic liver failure (ACLF) and decompensated cirrhosis (DC) patients. METHODS: During the period from December 2015 to July 2017, 280 patients with hepatitis B virus (HBV)-related ACLF (HBV-ACLF) and 132 patients with HBV-related DC (HBV-DC) who were admitted to our center were recruited consecutively into an observational study. Urine specimens were collected from all subjects and the levels of five urinary tubular injury biomarkers were detected,including neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), liver-type fatty acid binding protein (L-FABP), cystatin C (CysC), and kidney injury molecule-1 (KIM-1). Simultaneously, the patient demographics, occurrence and progression of AKI, and response to terlipressin therapy were recorded. All patients were followed up for 3 mo or until death after enrollment. RESULTS: AKI occurred in 71 and 28 of HBV-ACLF and HBV-DC patients, respectively (25.4% vs 21.2%, P = 0.358). Among all patients, the levels of four urinary biomarkers (NGAL, CysC, L-FABP, IL-18) were significantly elevated in patients with HBV-ACLF and AKI (ACLF-AKI), compared with that in patients with HBV-DC and AKI (DC-AKI) or those without AKI. There was a higher proportion of patients with AKI progression in ACLF-AKI patients than in DC-AKI patients (49.3% vs 17.9%, P = 0.013). Forty-three patients with ACLF-AKI and 19 patients with DC-AKI were treated with terlipressin. The response rate of ACLF-AKI patients was significantly lower than that of patients with DC-AKI (32.6% vs 57.9%, P = 0.018). Furthermore, patients with ACLF-AKI had the lowest 90 d survival rates among all groups (P < 0.001). CONCLUSION: AKI in ACLF patients is more likely associated with structural kidney injury, and is more progressive, with a poorer response to terlipressin treatment and a worse prognosis than that in DC patients.
Asunto(s)
Lesión Renal Aguda/etiología , Insuficiencia Hepática Crónica Agudizada/complicaciones , Cirrosis Hepática/complicaciones , Lipresina/análogos & derivados , Vasoconstrictores/uso terapéutico , Lesión Renal Aguda/tratamiento farmacológico , Lesión Renal Aguda/epidemiología , Lesión Renal Aguda/orina , Insuficiencia Hepática Crónica Agudizada/virología , Adulto , Biomarcadores/orina , Progresión de la Enfermedad , Femenino , Virus de la Hepatitis B/aislamiento & purificación , Humanos , Túbulos Renales/patología , Túbulos Renales/virología , Cirrosis Hepática/virología , Lipresina/uso terapéutico , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Factores de Riesgo , Terlipresina , Resultado del TratamientoRESUMEN
BACKGROUND: Hepatorenal syndrome is a fatal complication of advanced cirrhosis. Terlipressin is the most widely used treatment method, however, the therapy effects remain inconsonant. We aim to systematically assess the safety and efficacy of terlipressin for hepatorenal syndrome. METHODS: We conducted a systematic review and meta-analysis. Randomized controlled trials involving terlipressin for hepatorenal syndrome were included in a systematic literature search. Two authors independently assessed the studies for inclusion and extracted the data. A meta-analysis was conducted to estimate the safety and efficacy of terlipressin for hepatorenal syndrome. RESULTS: A total of 18 randomized controlled trials including 1011 patients were included. Hepatorenal syndrome reverse rate was 42.0% in the terlipressin group and 26.2% in the non-terlipressin group. Terlipressin had greater hepatorenal syndrome reverse rate and renal function improvement rate than placebo and octreotide in the management of HRS. Comparing to norepinephrine, terlipressin had similar efficacy, but with more adverse events. No significant difference of the efficacy was found between terlipressin and dopamine treatment. The subgroup analysis for type 1 HRS had the above same results, except that the adverse events were not significant different between norepinephrine group and terlipressin group. CONCLUSIONS: Terlipressin was superior to placebo and octreotide for reversal of hepatorenal syndrome and improving renal function, but it had no superiority comparing to norepinephrine.
Asunto(s)
Síndrome Hepatorrenal/tratamiento farmacológico , Lipresina/análogos & derivados , Vasoconstrictores/uso terapéutico , Síndrome Hepatorrenal/fisiopatología , Humanos , Riñón/fisiopatología , Lipresina/efectos adversos , Lipresina/uso terapéutico , Recurrencia , Terlipresina , Resultado del Tratamiento , Vasoconstrictores/efectos adversosRESUMEN
BACKGROUND: The aim of this study was to predict the occurrence of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and ascites. PATIENTS AND METHODS: We retrospectively evaluated 2-year data of 78 patients with cirrhosis and ascites (Child-Pugh B/C: 45/43). The mean arterial pressure (MAP) and cardiac output (CO) were measured in all patients just before administration of 2 mg of terlipressin and 30 min later. Systemic vascular resistance (SVR) was calculated as MAP/CO. ΔMAP, and ΔCO, and ΔSVR were defined as the percentage change of MAP, CO, and SVR, respectively, after terlipressin injection. Plasma renin activity (PRA) and plasma aldosterone were evaluated at baseline. Two multivariate models were used: one excluding (model 1) and one including (model 2) the Model of End-stage Liver Disease score. RESULTS: Higher ΔSVR, Model of End-stage Liver Disease score, and PRA were related independently to the severity of cirrhosis. Independent predictors of HRS at 12 and 24 months were ΔSVR (models 1/2: P=0.008/0.01 and 0.01/0.02, respectively), ΔCO (models 1/2: P=0.01/0.03 and 0.03/0.04, respectively), and PRA (models 1/2: P=0.04 and model 1: P=0.04, respectively). ΔSVR at 12 and 24 months (models 1/2: P=0.005/0.01 and 0.01/0.03, respectively) and ΔCO at 24 months (models 1/2: P=0.02/0.01, respectively) were related independently to survival. Patient groups with significantly higher probability of HRS and mortality were identified by certain cutoffs of ΔSVR (20.6 and 22.8%, respectively) and ΔCO (-10.6 and -11.8%, respectively). ΔSVR and ΔCO independently predicted survival in patients with the most advanced cirrhosis and infection-related survival. CONCLUSION: An increase in SVR by at least 20% and a decrease in CO at least 10% in response to terlipressin could predict HRS and mortality in patients with advanced cirrhosis.
Asunto(s)
Ascitis/etiología , Hemodinámica/efectos de los fármacos , Síndrome Hepatorrenal/etiología , Cirrosis Hepática/diagnóstico , Lipresina/análogos & derivados , Vasoconstrictores/administración & dosificación , Anciano , Área Bajo la Curva , Presión Arterial/efectos de los fármacos , Ascitis/mortalidad , Ascitis/fisiopatología , Gasto Cardíaco/efectos de los fármacos , Femenino , Síndrome Hepatorrenal/mortalidad , Síndrome Hepatorrenal/fisiopatología , Humanos , Modelos Lineales , Cirrosis Hepática/complicaciones , Cirrosis Hepática/mortalidad , Cirrosis Hepática/fisiopatología , Modelos Logísticos , Lipresina/administración & dosificación , Masculino , Persona de Mediana Edad , Análisis Multivariante , Valor Predictivo de las Pruebas , Modelos de Riesgos Proporcionales , Curva ROC , Reproducibilidad de los Resultados , Estudios Retrospectivos , Factores de Riesgo , Terlipresina , Factores de Tiempo , Resistencia Vascular/efectos de los fármacosRESUMEN
Terlipressin is an analogue of vasopressin that has potent vasoactive properties and has been available for use in most countries for nearly two decades. It has both established roles and emerging indications in the management of complications of decompensated chronic liver disease. We explore historic and emerging literature regarding the use of terlipressin for a range of indications including hepatorenal syndrome, portal hypertensive bleeding, and disruptions in sodium homeostasis. Novel methods of infusion-based terlipressin administration including the beneficial effect in reduction of adverse events are explored, in addition to new indications for the use of terlipressin in decompensated cirrhosis in an outpatient setting.
Asunto(s)
Hepatopatías/tratamiento farmacológico , Lipresina/análogos & derivados , Enfermedad Crónica , Humanos , Infusiones Intravenosas , Circulación Hepática/efectos de los fármacos , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/fisiopatología , Hepatopatías/fisiopatología , Lipresina/administración & dosificación , Lipresina/farmacología , Presión Portal/efectos de los fármacos , Circulación Renal/efectos de los fármacos , TerlipresinaRESUMEN
INTRODUCTION: Hepatorenal syndrome (HRS) is a unique form of acute kidney injury seen in cirrhotic patients and associated with significant mortality and morbidity. Despite its impact, diagnosis and treatment of HRS remains challenging and this review aims to assess and compare the available vasoconstrictors used as first-line treatment for HRS. Areas covered: A literature review was undertaken on the use of vasoconstrictors in HRS, using PubMed/Medline database searches of: 'hepatorenal syndrome', 'HRS' and 'vasoconstrictor'. Expert commentary: Current diagnosis criteria are based on an exclusion-based approach using serum creatinine as a biomarker. However, this method relies on the measurement over a sustained period of time resulting in delayed treatment. Using urine biomarkers, the revised acute kidney injury guidelines and novel plasma expanders may improve diagnosis and the implementation of time-sensitive management of HRS. Vasoconstrictors are the first-line treatment for HRS, in which terlipressin is the vasoconstrictor of choice supported by current guidelines and a substantial clinical evidence base over other vasoconstrictors, such as noradrenaline or midodrine plus octreotide. Future developments in dosage and administrative techniques for terlipressin may have an important role to play in maintaining clinical efficacy whilst improving tolerability in the management of HRS.
Asunto(s)
Síndrome Hepatorrenal/tratamiento farmacológico , Lipresina/análogos & derivados , Vasoconstricción/efectos de los fármacos , Vasoconstrictores/uso terapéutico , Biomarcadores/sangre , Biomarcadores/orina , Creatinina/sangre , Síndrome Hepatorrenal/diagnóstico , Síndrome Hepatorrenal/epidemiología , Síndrome Hepatorrenal/fisiopatología , Humanos , Lipresina/efectos adversos , Lipresina/uso terapéutico , Midodrina/uso terapéutico , Norepinefrina/uso terapéutico , Octreótido/uso terapéutico , Guías de Práctica Clínica como Asunto , Valor Predictivo de las Pruebas , Factores de Riesgo , Terlipresina , Resultado del Tratamiento , Vasoconstrictores/efectos adversosRESUMEN
PURPOSE: To study the effects of terlipressin (TP) infusion on systemic perfusion, estimated with pulsed-wave Doppler ultrasonography of systemic arteries, in a population of extremely low birth-weight (ELBW) preterm infants with vasoactive-resistant ductus arteriosus. METHODS: This prospective, observational cohort included, during five years, 12 ELBW infants with hemodynamically significant patent ductus arteriosus and absent or reversed diastolic flow at Doppler ultrasonography of systemic arteries, despite treatment and high-dose vasoactive support. We measured flow velocity of the anterior cerebral, right renal, and superior mesenteric arteries before and after TP infusion. Changes were evaluated by Spearman's rho coefficient analysis, Wilcoxon signed-rank, and Friedman test. RESULTS: Time-averaged mean velocity of the renal artery (P = .028) increased, while renal pulsatility (P = .010) and resistance (P = .004) indexes, and cerebral artery resistance index (P = .021) decreased after TP infusion. Time-averaged mean velocity of the anterior cerebral artery proportionately increased with dopamine dose (rho = 0.678; P = .015), but showed opposite shifts after TP (rho = -0.662; P = .024). CONCLUSIONS: These changes suggest that TP may improve systemic perfusion in the ELBW infants with vasoactive-resistant ductus arteriosus.
Asunto(s)
Arterias Cerebrales/efectos de los fármacos , Conducto Arterioso Permeable/fisiopatología , Lipresina/análogos & derivados , Arteria Mesentérica Superior/efectos de los fármacos , Arteria Renal/efectos de los fármacos , Ultrasonografía Doppler de Pulso/métodos , Velocidad del Flujo Sanguíneo/efectos de los fármacos , Arterias Cerebrales/diagnóstico por imagen , Estudios de Cohortes , Conducto Arterioso Permeable/tratamiento farmacológico , Femenino , Humanos , Recien Nacido con Peso al Nacer Extremadamente Bajo , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro , Lipresina/farmacología , Masculino , Arteria Mesentérica Superior/diagnóstico por imagen , Proyectos Piloto , Estudios Prospectivos , Arteria Renal/diagnóstico por imagen , Terlipresina , Ultrasonografía Doppler de Pulso/efectos de los fármacos , Vasoconstrictores/farmacologíaRESUMEN
Ascites represents the most common decompensating event in patients with liver cirrhosis. The appearance of ascites is strongly related to portal hypertension, which leads to splanchnic arterial vasodilation, reduction of the effective circulating volume, activation of endogenous vasoconstrictor systems, and avid sodium and water retention in the kidneys. Bacterial translocation further worsens hemodynamic alterations of patients with cirrhosis and ascites. The first-line treatment of uncomplicated ascites is a moderate sodium-restricted diet combined with diuretic treatment. In patients who develop refractory ascites, paracentesis plus albumin represents the most feasible option. Transjugular intrahepatic portosystemic shunt placement is a good alternative for selected patients. Other treatments such as vasoconstrictors and automated low-flow pumps are two potential options still under investigations. Ascites is associated with a high risk of developing further complications of cirrhosis such as dilutional hyponatremia, spontaneous bacterial peritonitis and/or other bacterial infections and acute kidney injury (AKI). Hepatorenal syndrome (HRS) is the most life-threatening type of AKI in patients with cirrhosis. The most appropriate medical treatment in patients with AKI-HRS is the administration of vasoconstrictors plus albumin. Finally, ascites impairs both the quality of life and survival in patients with cirrhosis. Thus, all patients with ascites should be evaluated for the eligibility for liver transplantation. The aim of this article is to review the management of patients with cirrhosis, ascites and HRS.